Published on
Mar 21, 2025
Selection of Frontline CDK4/6 Inhibitors Hinges on Patient Health Status in HR+/HER2– Metastatic Breast Cancer
In the hormone receptor (HR)–positive, HER2-negative metastatic breast cancer setting, frontline treatment with CDK4/6 inhibitor–based regimens are standard of care, and selecting between the approved CDK4/6 inhibitors should rely on patient- …
Source:
OncLive
-
Label Pending
